Labiotech.eu

lundbeck prexton therapeutics acquisition parkinsons

News and Trends 16 Mar 2018

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful. Danish pharma Lundbeck has decided to boost its pipeline with the acquisition of Prexton Therapeutics. The deal grants Lundbeck with global rights to foliglurax, a drug to reduce the “off” time periods when Parkinson’s motor […]

March 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Startup Scout 16 Mar 2018

This Belgian Biotech Could Speed Up Diagnoses for Neurodegenerative Diseases

Today we’re in Ghent, Belgium, home to several successful biotechs, including Ablynx, to visit ADx Neurosciences. The biotech specializes in biomarker assays for the detection of neurodegenerative diseases. Mission: Founded in 2011, ADx Neurosciences focuses on the development of antibodies to detect biomarkers in the diagnosis of neurodegenerative conditions from Alzheimer’s and Parkinson’s to traumatic brain injury. The anitbodies […]

March 16, 2018 - 2 minutesmins - By Alexander Burik

sofinnova partners industrial biotech fund

News and Trends 15 Mar 2018

French VC Raises the Biggest Green Biotech Fund in the World

Update (15/03/2018): Sofinnova Partners has closed its fund Industrial Biotech I at €125M, making it the largest fund dedicated to driving the transition towards a more sustainable fund. 03/03/2017 Sofinnova Partners has announced the first closing of a new fund, dedicated to renewable chemistry in industrial biotech, at €106 million. The largest biotech VC in […]

March 15, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Mar 2018

This Swedish Discovery Could Change the Way We Treat Diabetes

Swedish researchers have found that insulin-producing cells alone are not enough to fine-tune blood sugar levels. This could change the way diabetes treatments are designed. While it is known that certain clusters of cells in the pancreas called pancreatic islets influence the set point for blood sugar, the exact mechanisms are still unknown. The control of […]

March 15, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 15 Mar 2018

Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed?

Roche has positive clinical data in support of starting a Phase III trial in Alzheimer’s with an antibody initially developed by MorphoSys. However, the field is full of similar approaches that have failed. Roche plans to start a Phase III study to test MorphoSys’ Alzheimer’s treatment gantenerumab later this year, after encouraging preliminary clinical results. The drug […]

March 15, 2018 - 3 minutesmins - By Alexander Burik

Inside Labiotech 15 Mar 2018

Why is Victor Dillard, Founder of Desktop Genetics, reading Labiotech.eu?

Leaders & Readers: I had a chat with Victor Dillard about why he reads Labiotech.eu. He’s the COO/CFO, and Founder of Desktop Genetics, a leader in genome editing technology that aims to help researchers discover and treat the root genetic cause of human disease. This interview has just been lightly edited for grammar. Why and how […]

March 15, 2018 - 2 minutesmins - By Katherine Douglas

News and Trends 15 Mar 2018

New Antibiotic for MRSA Infections is Ready for US Clinical Trials

Update (15/03/2018): The FDA has granted Fast Track Designation to XF-73, an antibody being developed by Destiny Pharma against post-surgical MRSA infections. Originally published on 26/02/2018 Destiny Pharma’s antibiotic for post-surgical infections will begin its clinical development after the FDA accepted its Investigational New Drug application. Destiny Pharma wants to combat the growing antibiotic resistance […]

March 15, 2018 - 2 minutesmins - By Alex Dale

News and Trends 14 Mar 2018

A New Drug for Atrial Fibrillation Starts Human Testing in Europe

Update (14/03/2018): Acesion Pharma has started a Phase I clinical trial at the Centre for Human Drug Research (CHDR) in the Netherlands. The trial will test AP30663, a treatment for atrial fibrillation that the company believes has the potential to work better than every option currently available. Originally published on 2/8/2018 The Danish biotech Acesion Pharma […]

March 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Mar 2018

French Biotech Restores Vision in Humans with Subretinal Implant

Pixium Vision has successfully restored vision in three patients with age-related macular degeneration (AMD) using an implanted wireless device, offering significant improvements to their quality of life. Pixium Vision has restored vision in three patients with age-related macular degeneration (AMD), using a wireless microchip, named PRIMA, that is implanted under a patient’s retina. The technology marks a […]

March 13, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 13 Mar 2018

Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer

IO Biotech will test its immune modulator in combination with Merck’s checkpoint inhibitor Keytruda, known for curing former US President Jimmy Carter’s cancer. IO Biotech, based in Copenhagen, has entered an agreement with Merck (the US one) to enter a Phase I/II trial for treating lung cancer with IO’s immune modulator, IO102, and Merck’s checkpoint […]

March 13, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 13 Mar 2018

This Oxford Spin-out Could be Printing New Body Parts

The Oxford spin-out OxSyBio has secured £10M (€11,26M) to develop a 3D tissue printer that uses liquid droplets to design and regenerate tissues. Founded in 2014, OxSyBio is developing a technology to 3D print living tissues in order to replace body parts that are damaged by disease or injury. The substantial Series A funding was provided by Woodford Investment […]

March 13, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 13 Mar 2018

French Biotech Takes its Oral Diabetes Drug to Phase III

Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin. This oral drug has shown potential to lower glucose levels thanks to a mechanism of action that targets the pancreas, the liver and muscles simultaneously. The new trials will confirm whether these effects are maintained in a larger […]

March 13, 2018 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

This Belgian Biotech Could Speed Up Diagnoses for Neurodegenerative Diseases

French VC Raises the Biggest Green Biotech Fund in the World

This Swedish Discovery Could Change the Way We Treat Diabetes

Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed?

Why is Victor Dillard, Founder of Desktop Genetics, reading Labiotech.eu?

New Antibiotic for MRSA Infections is Ready for US Clinical Trials

A New Drug for Atrial Fibrillation Starts Human Testing in Europe

French Biotech Restores Vision in Humans with Subretinal Implant

Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer

This Oxford Spin-out Could be Printing New Body Parts

French Biotech Takes its Oral Diabetes Drug to Phase III

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!